Development of cabozantinib for the treatment of prostate cancer

por Vaishampayan, Ulka N
Publicado em 2014

The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies

por Vaishampayan, Ulka N.
Publicado no Am Soc Clin Oncol Educ Book (2016)

Satraplatin: leading the new generation of oral platinum agents

por Bhargava, Ashish, Vaishampayan, Ulka N
Publicado em 2009

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer

por Vaishampayan, Ulka N., Fontana, Joseph, Heilbrun, Lance K., Smith, Daryn, Heath, Elisabeth, Dickow, Brenda, Figg, William D.
Publicado em 2013

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [(18)F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer

por Vaishampayan, Ulka N., Tehrani, Omid S., Lawhorn-Crews, Jawana M., Heilbrun, Lance K., Dobson, Kimberlee, Smith, Daryn, Dickow, Brenda, Shields, Anthony F.
Publicado no Mol Imaging Biol (2017)

Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer

por Vaishampayan, Ulka N., Marur, Shanthi, Heilbrun, Lance K., Cher, Michael L., Dickow, Brenda, Smith, Daryn W., Al Hasan, Samir A., Eliason, James
Publicado em 2009

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction

por Flaig, Thomas W., Plets, Melissa, Hussain, Maha H. A., Agarwal, Neeraj, Mitsiades, Nicholas, Deshpande, Hari A., Vaishampayan, Ulka N., Thompson, Ian M.
Publicado no JAMA Oncol (2017)

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

por Shapiro, Geoffrey I., Vaishampayan, Ulka N., LoRusso, Patricia, Barton, Jeremy, Hua, Steven, Reich, Steven D., Shazer, Ronald, Taylor, Carrie T., Xuan, Dawei, Borghaei, Hossein
Publicado no Invest New Drugs (2017)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

por Kim, Joseph W., Cardin, Dana B., Vaishampayan, Ulka N., Kato, Shumei, Grossman, Steven R., Glazer, Peter M., Shyr, Yu, Ivy, S. Percy, LoRusso, Patricia M.
Publicado no Oncologist (2021)

SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE COMBINATION OF SORAFENIB AND TANESPIMYCIN

por Vaishampayan, Ulka N., Burger, Angelika M., Sausville, Edward A., Heilbrun, Lance K., Li, Jing, Horiba, Naomi, Egorin, Merrill J., Ivy, Percy, Pacey, Simon, Lorusso, Patricia M.
Publicado em 2010

Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer

por Vaishampayan, Ulka N., Podgorski, Izabela, Heilbrun, Lance K., Lawhorn-Crews, Jawana M., Dobson, Kimberlee C., Boerner, Julie, Stark, Karri, Smith, Daryn W., Heath, Elisabeth I., Fontana, Joseph A., Shields, Anthony F.
Publicado no Clin Cancer Res (2018)

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

por Swami, Umang, Velho, Pedro Isaacsson, Nussenzveig, Roberto, Chipman, Jonathan, Santos, Victor Sacristan, Erickson, Stephanie, Dharmaraj, Divya, Alva, Ajjai Shivaram, Vaishampayan, Ulka N., Esther, John, Hahn, Andrew W., Maughan, Benjamin Louis, Antonarakis, Emmanuel S., Agarwal, Neeraj
Publicado no Eur Urol (2020)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial

por Vaishampayan, Ulka N., Heilbrun, Lance K., Monk, Paul, Tejwani, Sheela, Sonpavde, Guru, Hwang, Clara, Smith, Daryn, Jasti, Pallavi, Dobson, Kimberlee, Dickow, Brenda, Heath, Elisabeth I., Semaan, Louie, Cher, Michael L., Fontana, Joseph A., Chinni, Sreenivasa
Publicado no JAMA Netw Open (2021)

Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy

por Necchi, Andrea, Pond, Gregory R., Giannatempo, Patrizia, Di Lorenzo, Giuseppe, Eigl, Bernhard J., Locke, Jenn, Pal, Sumanta K., Agarwal, Neeraj, Poole, Austin, Vaishampayan, Ulka N., Niegisch, Guenter, Hussain, Syed A., Singh, Parminder, Bellmunt, Joaquim, Sonpavde, Guru
Publicado no Clin Genitourin Cancer (2014)

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database

por Moschini, Marco, Xylinas, Evanguelos, Zamboni, Stefania, Mattei, Agostino, Niegisch, Günter, Yu, Evan Y., Bamias, Aristotelis, Agarwal, Neeraj, Sridhar, Srikala S., Sternberg, Cora N., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Bellmunt, Joaquim, Galsky, Matthew D., Montorsi, Francesco, Necchi, Andrea
Publicado no Eur Urol Oncol (2019)

Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population

por Khambati, Husain K., Choueiri, Toni K., Kollmannsberger, Christian K., North, Scott, Bjarnason, George A., Vaishampayan, Ulka N., Wood, Lori, Knox, Jennifer J., Tan, Min-Han, MacKenzie, Mary J., Donskov, Frede, Rini, Brian I., Heng, Daniel Y.C.
Publicado em 2014

Cisplatin versus non-cisplatin based first-line chemotherapy for advanced urothelial carcinoma previously treated with peri-operative cisplatin

por Locke, Jennifer A, Pond, Gregory Russell, Sonpavde, Guru, Necchi, Andrea, Giannatempo, Patrizia, Paluri, Ravi Kumar, Niegisch, Guenter, Albers, Peter, Buonerba, Carlo, di Lorenzo, Giuseppe, Vaishampayan, Ulka N., North, Scott A., Agarwal, Neeraj, Hussain, Syed A., Eigl, Bernhard J.
Publicado no Clin Genitourin Cancer (2015)

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

por Heng, Daniel Y C, Xie, Wanling, Regan, Meredith M, Harshman, Lauren C, Bjarnason, Georg A, Vaishampayan, Ulka N, Mackenzie, Mary, Wood, Lori, Donskov, Frede, Tan, Min-Han, Rha, Sun-Young, Agarwal, Neeraj, Kollmannsberger, Christian, Rini, Brian I, Choueiri, Toni K
Publicado em 2013

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study

por Harshman, Lauren C, Xie, Wanling, Bjarnason, Georg A, Knox, Jennifer J, MacKenzie, Mary, Wood, Lori, Srinivas, Sandy, Vaishampayan, Ulka N, Tan, Min-Han, Rha, Sun-Young, Donskov, Frede, Agarwal, Neeraj, Kollmannsberger, Christian, North, Scott, Rini, Brian I, Heng, Daniel Y C, Choueiri, Toni K
Publicado em 2012

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

por Cheng, Heather H., Gulati, Roman, Azad, Arun, Nadal, Rosa, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta K., Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia A., Montgomery, R. Bruce, Galsky, Matthew D., Antonarakis, Emmanuel S., Chi, Kim N., Yu, Evan Y.
Publicado no Prostate Cancer Prostatic Dis (2015)